United Therapeutics Corporation (Nasdaq: UTHR), a leading public benefit corporation, has disclosed that Patrick Poisson, Executive Vice President of Technical Operations, will participate in a fireside chat session at the…
Epsilogen and Lonza Achieve Breakthrough in Manufacturing IgE Antibody for Ovarian Cancer Treatment Epsilogen, a leader in developing IgE antibodies for cancer therapy, and Lonza, a global partner in pharmaceutical…
PQE Group eagerly anticipates participating in the 2024 PDA India Chapter Annual Meeting in Hyderabad from March 11-15, focusing on critical issues in the pharmaceutical and medical device sectors. The…
Vivani Medical, Inc. (Nasdaq: VANI), a pioneering biopharmaceutical company in the preclinical stage, has recently announced a significant move towards advancing its innovative long-term drug implants. In a registered direct…
President and CEO of Bio-Techne, Kim Kelderman, commented on the results, acknowledging the team’s resilience in a challenging environment. He expressed optimism regarding the stabilization observed in China and reiterated…
Shionogi & Co., Ltd. (Headquartered in Osaka, Japan; CEO: Isao Teshirogi, Ph.D.; referred to as “Shionogi” hereafter) has initiated the second phase of collaboration with Nagasaki University (Located in Nagasaki,…
Shionogi & Co., Ltd. (Head Office: Osaka, Japan; Chief Executive Officer: Isao Teshirogi, Ph.D.; hereafter “Shionogi”) announced that Shionogi and Osaka University (Location: Suita, Osaka, President: Shojiro Nishio) have established…
WuXi Biologics (2269.HK), a prominent global Contract Research, Development, and Manufacturing Organization (CRDMO), proudly announces the reception of three esteemed International Organization for Standardization (ISO) certifications at its Ireland facility.…
Astellas Pharma Inc. (TSE: 4503, President and CEO: Naoki Okamura, “Astellas”) has initiated dosing for the first patient in the STARLIGHT™ 2 Phase 3 pivotal study for fezolinetant, an investigational…
Roche (SIX: RO, ROG; OTCQX: RHHBY) has revealed the findings from Stage 1 of the National Institutes of Health (NIH)-sponsored pivotal Phase III OUtMATCH study, assessing the effectiveness and safety…
AbbVie Inc. (NYSE: ABBV) and OSE Immunotherapeutics SA (ISIN: FR0012127173; Mnemo: OSE), a clinical-stage immunotherapy company, have announced a strategic partnership aimed at developing OSE-230, a monoclonal antibody designed to…
AbbVie (NYSE: ABBV) announces today that the U.S. Food and Drug Administration (FDA) has granted Priority Review for the supplemental Biologics License Application (sBLA) concerning epcoritamab-bysp, a subcutaneously administered T-cell…